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Abstract
Background: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with
tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor
Radionuclide Therapy (PRRT), which has also been suggested to be a useful treatment for MTC, is usually well
tolerated, but evidence on its effectivity is very limited.
Methods: Retrospective evaluation of treatment effects of PRRT in a highly selected group of MTC patients, with
progressive disease or refractory symptoms. In addition, a retrospective evaluation of uptake on historical 111In-
DTPA-octreotide scans was performed in patients with detectable tumor size > 1 cm.
Results: Over the last 17 years, 10 MTC patients were treated with PRRT. Four out of 10 patients showed stable
disease at first follow-up (8 months after start of therapy) whereas the other 6 were progressive. Patients with stable
disease were characterized by a combination of both a high uptake on 111In-DTPA-octreotide scan (uptake grade ≥
3) and a positive somatostatin receptor type 2a (SSTR2a) expression of the tumor by immunohistochemistry.
Retrospective evaluation of historical 111In-DTPA-octreotide scans of 35 non-treated MTC patients revealed low
uptake (uptake grade 1) in the vast majority of patients 31/35 (89%) with intermediate uptake (uptake grade 2) in
the remaining 4/35 (11%).
Conclusions: PRRT using 177Lu-octreotate could be considered as a treatment in those patients with high uptake
on 111In-DTPA-octreotide scan (uptake grade 3) and positive SSTR2a expression in tumor histology. Since this high
uptake was present in a very limited number of patients, this treatment is only suitable in a selected group of MTC
patients.
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Background
Patients and treatment
Medullary thyroid carcinoma (MTC), originating from
calcitonin (CT)-producing parafollicular C cells, is a rare
form of thyroid cancer that accounts for less than 5% of
thyroid carcinomas [1]. In 25% of the cases, MTC is part
of inherited disorders, such as multiple endocrine
neoplasia 2a, 2b or familial MTC involving RET germline
mutations. Locally unresectable tumor or distant metasta-
ses have limited systemic treatment options [2, 3]. Al-
though the tyrosine kinase inhibitors (TKI) vandetanib
and cabozantinib have been shown to improve
progression-free survival (PFS) [hazard ratio (HR), 0.46
and HR 0.28 respectively], grade 3 or 4 adverse events
occur in a large number of patients (44% in vandetanib,
69% in cabozantinib) [3, 4]. Therefore, alternative systemic
treatment options with less side effects are needed.
Somatostatin receptor (SSTR) expression has been re-
ported in up to 85% of MTCs, particularly SSTR
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subtypes 2, 3 and 5 [5–8], with 49% of MTCs showing ex-
pression of the SSTR2a subtype [5]. Somatostatin receptor
scintigraphy with 111In-DTPA-octreotide (Octreoscan®),
which has high affinity for SSTR2a, has been reported to
show lesional uptake in 57–65% of MTC patients [9–11].
Therefore, targeting the tumor with a radionuclide using
somatostatin analogs as a ligand seems to be an attractive
option.
In midgut neuroendocrine tumors, peptide receptor
radionuclide therapy (PRRT) resulted in a PFS rate at 20
months of 65% vs. 11% in the control group [12].
In MTC there is limited experience with PRRT treat-
ment. A phase II trial in 31 patients with 90Y-DOTA-
TOC, which also targets SSTR2a, reported a partial
response (PR) in 29% of the patients [13]. In a second
trial treating 7 MTC patients with 177Lu-octreotate, 3
patients had PR, 3 patients had stable disease (SD) and 1
patient progressive disease (PD) [14]. These results sug-
gest that PRRT might be a useful treatment in patients
with MTC, although the total number of treated patients
is very limited so far. For that reason, we performed a
retrospective evaluation of treatment with 177Lu-octreo-
tate in our center, where it was used in a highly selected
group of 10 MTC patients with progressive disease or
high risk tumor localization. In addition, we evaluated
possible predictors and pitfalls of 177Lu-octreotate treat-
ment in MTC.
Methods
We retrospectively studied 10 consecutive patients with
histologically proven MTC. Patients treated with
177Lu-octreotate between 2000 and 2017 had progressive
metastatic MTC according to Response Evaluation Cri-
teria In Solid Tumors 1.1 [15] (RECIST) or had high risk
tumor localization (intracardial and compressive cervical
tumor). The study was approved by the Institutional Re-
view Board of the Erasmus Medical Center (127.545/
1993/84) and written informed consent was obtained
from participants.
We used the methods for 177Lu-octreotate therapy as
described in detail previously [16]. Patients received an
average of 4 cycles of 177Lu-octreotate, up to a cumula-
tive dose of 27,8 to 29,6 GBq, with an interval of 6 to 10
weeks [17, 18]. Response to treatment was evaluated at a
median of 8 months (3 months after the last cycle with
177Lu-octreotate) and subsequently at 3 monthly
follow-up visits, assessing clinical, biochemical and im-
aging parameters. The world health organization
(WHO) performance status was scored at baseline and
during follow-up by the treating physician.
End points
PFS was computed as the time from treatment initiation
to progression, assessed by objective tumor response
RECIST 1.1 criteria, clinical disease progression accord-
ing to the treating physician, death or last documented
patient visit [15]. Overall survival (OS) was computed as
the time from treatment initiation to death, or until the
last documented patient visit. Adverse events were
scored according to Common Terminology Criteria for
Adverse Events [19].
111In-DTPA-octreotide scans
We retrospectively reviewed 111In-DTPA-octreotide
scans between 1999 and 2011 of non-treated MTC pa-
tients that were performed in metastatic MTC. Although
not part of the regular follow-up of MTC [2],
111In-DTPA-octreotide scans were performed for tumor
staging in most of these patients. Uptake was scored ac-
cording to the Krenning score [18, 20]: uptake grade 1 =
uptake < normal liver uptake; uptake grade 2 = uptake
equal to normal liver uptake; uptake grade 3 = uptake >
normal liver uptake; uptake grade 4 = uptake > normal
spleen or kidneys uptake (Fig. 1).
Immunohistochemistry SSTR2a
SSTR2a immunohistochemistry was retrospectively per-
formed in the patients treated with 177Lu-octreotate.
Formalin fixed paraffin embedded (FFPE) tissue slices of
one or two tissue biopsies per patient were immuno-
stained for SSTR2a using the Ventana BenchMark
ULTRA stainer (Ventana, Tucson, Arizona, USA), ac-
cording to the protocol provided by the manufacturer.
The rabbit monoclonal anti-sst2 antibody (BioTrend,
Köln, Germany) was used at a dilution of 1:25. Normal
pancreatic tissue served as a positive control. SSTR2a
expression was scored according to the percentage of
cells with positive immunohistochemistry (0: absent
staining; 1: weak staining < 30% of cells; 2: moderate
staining 30–60% cells; 3: strong staining> 60% of cells)
and localization cytoplasm or cell membrane [21]. Scor-
ing was done by two independent pathologists (F.H. N
and M.F.V), who were blinded to each other’s findings
and patient data.
Laboratory measurements
RET gene analysis to exclude multiple endocrine neopla-
sia 2a, was performed in DNA of 6/10 patients. RET
analysis on the tumor tissue was not performed in this
retrospective study. Calcitonin (CT) and carcinoembryo-
nic antigen (CEA) are useful tumor markers of residual
disease and their doubling time is an indicator for prog-
nosis [22]. CT was measured on an Immulite 2000XPi
immunoassay system (Siemens Healthcare Diagnostics,
Los Angeles, USA) by chemoluminescence method.
CEA was measured by an electrochemiluminescence im-
munoassay on a Cobas e601 immunoassay analyzer
(Roche Diagnostics GmbH, Penzberg, Germany). The
Beukhof et al. BMC Cancer          (2019) 19:325 Page 2 of 8
inter-day coefficient of variation of CT and CEA were
7.8 and 5%, respectively.
Statistics
We refrained from statistics due to limited patient number.
PFS and OS was determined with Kaplan-Meier BM SPSS
Statistics for Windows v23 (IBM Corp., Armonk, NY).
Results
Baseline
Ten patients were treated with 177Lu-octreotate. They had
a median age 62 [range 19–75] years and 4/10 (40%) were
male (Table 1). The indication for 177Lu-octreotate was
progressive MTC according to RECIST-criteria in 8/10
(80%) of patients. One patient was treated for intracardial
metastasis with biochemical progression and one patient
for large cervical inoperable tumor load. None of the
tested patients showed germline mutations in the RET
proto-oncogene (Table 1). Eight out of 10 (80%) patients
had a baseline WHO performance status of 1, whereas the
other 2 treated patients had a WHO status of 3 (Table 1).
Three out of 10 (30%) patients had an endocrine paraneo-
plastic syndrome due to tumor-produced adrenocortico-
tropic hormone (ACTH), resulting in ectopic Cushing’s
disease, parathyroid hormone-related protein (PTH-rp)
resulting in severe hypercalcemia and dopamine without
clinical sequelae.
End points
Two patients showed PD during the third treatment
cycle and were withheld from further treatment. In total,
median PFS was 0.70 years [range 0.3–12.0], 1 patient is
still in follow-up with stable disease 1.6 years after start
of treatment. In total, 6 out of 10 (60%) patients had
tumor progression at first follow-up (8 months) after
start of treatment. The patient with large cervical inop-
erable tumor showed PD of distant metastasis, however
the thyroid tumor mass with focal grade 3 expression on
111In-DTPA-octreotide scan remained stable.
Four out of 10 (40%) patients had SD at first
follow-up. This includes, the patient with intracardial
tumor mass with SD at start of therapy. Overall, SD was
maintained for a median of 1.4 years [range 0.7–12.0]
(Fig. 2). One patient with RECIST progressive disease
before start of PRRT had enduring sustained SD for 12
years and died from an unrelated disease (fibrosarcoma).
Overall median OS was 1.14 years [range 0.4–12.0]. Two
patients are still alive at 1.4 and 1.6 years since start of
PRRT. The median OS in SD patients was 1.8 years
[0.8–12.0].
Baseline median CT doubling time and CEA doubling
time showed a wide range making it difficult to interpret
due to small patient number. Patients with SD seemed
to have a trend to shorter CT and CEA doubling time
than patients with PD (Table 1). None of the patients
showed a decrease in CT or CEA levels of ≥50% after
treatment with 177Lu-octreotate. Three of the four pa-
tients with SD showed a 20–40% decrease of CT and/or
CEA levels with sustained response. One out of these
four patients showed an initial rise of tumor markers
in the first 5 months, which was followed by a sus-
tained decrease in both tumor markers. Three out of
the 6 patients with PD showed loss of correlation
with CT (no increase in tumor marker, despite pro-
gressive disease) (Table 2). In one out of 6 patients
there was loss of CEA tumor marker, but sustained
CT response.
Predictors of response
All 4 patients with SD showed high uptake on the
111In-DTPA-octreotide scans (uptake grade ≥ 3) and
showed moderate to positive SSTR2a receptor expres-
sion on histological examination (Table 2).
All patients with PD had negative tumor STTR2 ex-
pression in the tissue biopsy. Patients with PD had
A B
Fig. 1 The principle of Krenning uptake on 111In-DTPA-octreotide scans. a) MTC in neck region seems to have significant uptake. b) However
when compared to normal liver uptake it is scored as Grade 2 uptake
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variable uptake on 111In-DTPA-octreotide scans, as well
as on post therapy scans (Table 2). Two out of 6 patients
(33%) showed uptake grade 3 on 111In-DTPA-octreotide
scan. In one of these patients we identified a remarkable
SSTR2a positive staining of tumor endothelium. In 1 out
of the 6 patients (17%) non-homogenous uptake of
111In-DTPA-octreotide scan, with loss of uptake in some
metastasis was observed. In the other patients, 1/6 (17%)
showed uptake grade 2 and 2/6 (33%) showed uptake
grade 1 (Fig. 3).
111In-DTPA-octreotide scans
None of the 35 retrospectively evaluated non-treated
MTC patients had an 111In-DTPA-octreotide scan with
higher uptake in the metastases than in the liver (grade ≥
3). Only 4/35 (11%) patients showed moderate uptake
(grade 2). In the majority of patients 31/35 (89%), the
tumor was detectable. (Fig. 3).
Symptoms and adverse events
There was no improvement of symptoms or paraneo-
plastic syndrome, neither in the stable disease patients
nor in the progressive patients. Common grade 1 side ef-
fects included diarrhea, fatigue, mild anorexia and mild
hair loss, occurring in the majority of patients. Grade 2
diarrhea occurred in 1 out of 10 patients. One patient
developed grade 3 adverse event: hemoptysis, presum-
ably due to progression of pulmonary metastasis.
Discussion
This study reports the results of 10 patients with metas-
tasized MTC that were treated with PRRT using
177Lu-octreotate. Only 4 patients showed SD at first
follow-up at 8 months after start of therapy. All of these
4 patients with SD showed high uptake (Krenning up-
take grade ≥ 3) on the 111In-DTPA-octreotide scan as
well as SSTR2a receptor expression in the tumor upon
immunohistochemistry staining, whereas none of the
Table 1 Patient characteristics
Overall
(N = 10)
Stable disease
(N = 4)
Progressive disease
(N = 6)
Age years median [range] 63 [19–75] 69 [19–75] 60 [42–73]
Male N (%) 4/10 (40%) 1/4 (25%) 3/6 (50%)
RET
Wild-type N (%) 6/10 (60%) 3/4 (75%) 3/6 (50%)
Unknown N (%) 4/10 (40%) 1/4 (25%) 3/6 (50%)
Disease extent
Moderate 8/10 (80%) 2/4 (50%) 6/6 (100%)
Extensive 2/10 (20%) 2/4 (50%) 0/6 (0%)
Tumormarkers
Calcitonin DT years, [range] 2.4 [0.6–4.1] 0.8 [0.6–4.1] 2.6 [2.4–2.9]
CEA DT years, [range] 1.9 [0.6–7.4] 1.9 [1.2–2.1] 4.0 [0.6–7.4]
PRRT indication
PD 8/10 (70%) 3/4 (75%) 5/6 (83%)
Tumor localization❶ 2/10 (30%) 1/4 (25%) 1/6 (17%)
WHO
1 8/10 (80%) 3/4 (75%) 5/6 (83%)
3 2/10 (20%) 1/4 (25%) 1/6 (17%)
Hormonal functioning ❷ 3/10 (30%) 1/4 (25%) 2/6 (33%)
Endpoints
Death from MTC 7/10 2/4 (50%) 5/6 (83%)
Death other cause❸ 1/10 1/4 (25%) 0/4 (0%)
Alive 2/10 1/4 (25%) 1/4 (25%)
Abbreviations: CEA, carcinoembryonic antigen; DT, doubling time; MTC, medullary thyroid carcinoma; N, number; PRRT, peptide receptor radionuclide therapy;
RET, rearranged during transfection; WHO, world health organization performance status
Footnote:
❶ Intracardial metastasis and biochemical progression; inoperable cervical tumour load
❷ Ectopic ACTH; PTH-rp; dopamine
❸ Fibrosarcoma
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remaining 6 patients that had PD at first follow-up had
such a combination of high uptake plus SSTR2a receptor
expression in the tumor. 177Lu-octreotate was well toler-
ated, in accordance to previous publications [12].
Our results are similar to the results reported with
90Yttrium-labelled octreotide treatment [13], where par-
tial response (PR) was defined as any decrease in tumor
marker. In the present study this was identified in 3 out
of 10 (30%) patients. Moreover, median OS was in a
similar range, i.e. 1.3 years in patients treated with
90Yttrium-labelled octreotide vs. 1.14 years in our study
population. However, 90Yttrium-labelled octreotide is
known to cause more severe hematological and renal
side effects [13].
Although patient numbers are small, the study by
Vaisman [14], suggests a better treatment response
compared to the present study, where 6/10 (60%) pa-
tients had PD. PFS was 6.38 years in the study by
Vasiman et al. versus 0.70 years in our patient popula-
tion. This suggests that our study population included
patients with more aggressive MTC. Several other
study characteristics support this hypothesis. Firstly,
the present study included 3/10 (30%) patients with
paraneoplastic endocrine syndrome, which is a
well-known poor prognostic factor [23]. Secondly 4/
10 (40%) patients showed loss of tumor marker ex-
pression, which is also associated with worse progno-
sis [24]. And finally, our patients were much older
(median age of 62 years [range 19–75] in the current
study versus 35 years [range 20–78] in the study by
Vaisman et al.), which is relevant, as age is an im-
portant determinant of prognosis in MTC [25].
The hypothesis that our study population had an ag-
gressive form of MTC is also supported by the very low
PFS in the present study, 0.7 years compared to 1.6 years
in the placebo group of the phase III trial of the ZETA
study (vandetanib) [4].
Predictors of response
All 4 patients with SD were characterized by high uptake
on 111In-DTPA-octreotide scan (grade ≥ 3) and SSTR2a
tumor expression.
Table 2 Clinical characteristics and outcome
Overall
(N = 10)
Stable disease
(N = 4)
Progressive disease
(N = 6)
Uptake Grade≥ 3 7/10 (70%) 4/4 (100%) 3/6 (50%)
Uptake Grade < 3 3/10 (30%) 0/0 (0%) 3/6 (50%)
SSTR2a tumour expression 4/10 (40%) 4/4 (100%) 0/6 (0%)
Loss of correlation CT 3/6 (50%) 0/4 (0%) 3/6 (50%)
Abbreviations: Calcitonin, CT; Grade 3: uptake > normal liver uptake; N, number; SSTR, somatostatin receptor
Fig. 2 Progression free survival. Abbreviations: PD, progressive disease, SD, stable disease. Footnote: SD censored patient is still in follow-up with
stable disease 1.6 years after start of treatment
Beukhof et al. BMC Cancer          (2019) 19:325 Page 5 of 8
In the previously mentioned trial with 90Yttrium-la-
belled octreotide [14], tumor response did not correl-
ate with 111In-DTPA-octreotide uptake. In that study
only 2 out of 9 (22%) of the responders had a high
uptake (grade > 3) vs. 6 out of 22 (27%) of the
non-responders. However, response was based on
tumor marker decrease and not scored according to
RECIST criteria. SSTR2a staining on the tumor speci-
men was not performed.
Retrospective evaluation of historical 111In-DTPA-oc-
treotide scans shows that only very few MTC patients
have 111In-DTPA-octreotide scans with uptake grade ≥ 3.
Other papers have reported uptake in up to 65% of MTC
patients, but none of these studies reported a formal up-
take grade with comparison to hepatic uptake [9, 10].
Despite uptake grade ≥ 3 on 111In-DTPA-octreotide
scan, we identified 3/6 (50%) patients in the PD group
who had negative SSTR2a tumor staining upon immu-
nohistochemistry. This might be explained by
non-homogenous tumor expression of the SSTR2a re-
ceptor. Moreover, in one of these patients with PD, we
identified SSTR2a immunohistochemistry uptake in the
vascular endothelium instead of in the tumor itself,
which may have resulted in uptake on 111In-DTPA-oc-
treotide scan. This phenomenon is described in a variety
of other human tumors [26, 27].
In the present study SSTR2a expression was absent
in all 6 patients with PD, which suggests that lack of
SSTR2a expression in the tissue biopsy may be a bad
prognostic sign in patients with MTC. This is in line
with pancreatic NET (P-NETs) and GEP-NETs, where
low SSTR2a tumor expression has been shown to be
associated with poor outcome and more aggressive
grades of tumor [28–30]. In a retrospective study in
97 patients with MTC, SSTR2a expression was signifi-
cantly correlated with the presence of lymph node
metastasis. However, prognosis was not investigated
[8]. In MTC patients, stage IV, 10-year survival rates
for SSTR2a negative patients was 43% versus 96% for
SSTR2a positive patients [31].
Limitations and future perspectives
A limitation of the present retrospective study is the
small number of patients and the heterogeneity between
patients. Despite this, as very limited data of PRRT in
MTC patients are currently available, the present study
provides valuable insights about which patients might
potentially benefit from PRRT. In addition, it clearly il-
lustrates that this therapy may only be suitable for a
highly selected group of patients.
In the present study, 111In-DTPA-octreotide scans
were used to evaluate SSTR2a uptake in 35 non-treated
patients, demonstrating very limited uptake compared to
the liver in the majority of patients. The nowadays more
commonly used 68Ga-DOTATATE PET scans have bet-
ter imaging properties due to pharmacological (higher
affinity to SSTR2a), technical (e.g. positron imaging, at-
tenuation correction), as well as physical (higher gamma
energies) differences and are more useful for more pre-
cise staging of the patient [32–34]. However, it is not
likely that routine 68Ga-DOTATATE PET scans would
have resulted in a higher percentage of patients with a
more favorable uptake compared to the liver. In pul-
monary and gastroenteropancreatic neuroendocrine tu-
mours only 3 out of 78 (4%) patients were misclassified
by 111In-DTPA-octreotide scans [35].
The role of other pharmaceuticals in imaging and
treatment of MTC, such as metaiodobenzylguanidine
(MIBG), is limited due to low sensitivity (30%) [36, 37]
and the small number of patients treated with
I-131-MIBG [38, 39].
Conclusion
PRRT using 177Lu-octreotate could be considered in
MTC patients with both a high tumor uptake (≥grade 3)
on 111In-DTPA-octreotide scan as well as tumor SSTR2a
receptor expression by immunohistochemistry. Further
research is needed to evaluate the effectiveness in these
patients. Our retrospective data of 35 non-treated MTC
patients, suggest that only minority of patients are eli-
gible for 177Lu-octreotate therapy.
Fig. 3 Uptake on 111In-DTPA-octreotide scans in patients treated with PRRT and of 35 non-treated patients with metastasized MTC. Abbreviations:
N, number; PRRT, peptide receptor radionuclide therapy; SRS, somatostatin receptor scintigraphy (111In-DTPA-octreotide scans)
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